CMV pp65 mRNA Lipid Particle Vaccine

**Semantic type:** Immunologic Factor|Pharmacologic Substance

**Definition:** An off-the-shelf (OTS) lipid particle (LP)-based cancer priming vaccine containing messenger RNA (RNA) encoding the human cytomegalovirus (CMV) matrix protein pp65 (65 kDa lower matrix phosphoprotein; UL83), with potential immunostimulatory and antineoplastic activities. Upon administration of CMV pp65 mRNA LP vaccine, the mRNA is taken up, translated and presented by antigen presenting cells (APCs), mainly dendritic cells (DCs). This may result in a specific cytotoxic T-lymphocyte (CTL) response against CMV pp65-expressing tumor cells leading to tumor cell lysis. The CMV pp65 protein is the primary component of the enveloped subviral particle of CMV and is expressed in certain tumor types.

**Synonyms:** - CMV pp65 RNA-LPs - CMV pp65 RNA-loaded Lipid Particles - CMV pp65 mRNA Vaccine - pp65 RNA LP - pp65 RNA LPs - pp65 RNA-LP Vaccine - pp65 mRNA-loaded LPs